Gen-Probe HIV test
This article was originally published in The Gray Sheet
Executive SummaryFirm announces FDA approval of the Aptima HIV-1 RNA qualitative genetic test Oct. 5. Gen-Probe plans to launch the test in November with its Aptima HCV RNA qualitative assay for the hepatitis C virus. The tests "fill a small-yet-important medical niche" in detecting the presence of viral genetic material, said Steve Kondor, the firm's VP-sales & marketing. The HIV test is the first approved nucleic acid test indicated to aid in the diagnosis of HIV-1 infection and to confirm infections in certain patients, according to Gen-Probe. Bayer has sold the HCV test as a co-exclusive marketer under the Versant brand since its approval in 2002. Gen-Probe has not marketed the HCV test before...
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.